Retinoblastoma: the evidence does matter.

摘要

We are responding to a letter that appeared in your recent issue [1], which contains a number of major inaccuracies regarding retinoblastoma. Similar speculations and misleading conclusions can be found in two previous papers by the same first author [2,3]. We feel that we can provide enough evidence and expertise from our own work to challenge such misconstructions. We provide genetic testing for mutations in the RBI gene (MDVI 180200) through a not-for-profit corporation, Retinoblastoma Solutions. Patient samples are sent to us from around the world (22 countries, 6 continents) and to date we have served over 1080 unique retinoblastoma families. Our own and our collaborators' research has contributed to the understanding of the mechanisms of retinoblastoma, and cancer in general.